Case Studies in Bioethics
Learning Objectives
- Apply core bioethics principles (consent, dignity, justice) to five landmark real-world case studies.
- Explain the ethical and legal significance of the HeLa cell line and Dolly the sheep.
- Analyze the CRISPR gene editing controversy and the GMO food debate through an ethics lens.
- Evaluate the ethical dimensions of human embryonic stem cell research.
- Compare how each case study changed subsequent law, policy, or scientific practice.
- Synthesize lessons across cases into general principles for evaluating new biotech ethical dilemmas.
Quick Answer
Bioethics is best learned through real cases, because abstract principles like "informed consent" or "justice" only become clear once you see what happens when they are violated or tested. This chapter walks through five landmark cases — the HeLa cell controversy, Dolly the sheep, CRISPR gene editing, the GMO food debate, and human embryonic stem cell research — each of which forced society to draw a new ethical or legal line. Together they show a pattern: technology usually moves faster than the rules governing it, and each case study is the moment society caught up.
Case 1: The HeLa Cell Controversy — Consent and Ownership of Biological Material
In 1951, cells were taken from a cervical cancer biopsy of Henrietta Lacks, an African American woman being treated at Johns Hopkins Hospital, without her knowledge or consent — standard practice for the era, but a clear ethical violation by today's standards. Her cells, later called HeLa cells, turned out to be "immortal": unlike normal human cells, they could divide indefinitely in culture, making them enormously valuable for research. HeLa cells have since been used in polio vaccine development, cancer research, and countless other studies, generating enormous scientific and commercial value — none of which benefited the Lacks family for decades.
Why it matters: This case crystallized two enduring bioethics questions — do patients have a right to control what happens to tissue removed during treatment, and should they share in any commercial value derived from it? It became a foundational reference for Institutional Review Boards (IRBs) and modern informed consent requirements, and continues to inform debates about biobanking and genetic data ownership today.
Case 2: Dolly the Sheep — Cloning and the Limits of Manipulating Life
In 1996, Scottish scientists used somatic cell nuclear transfer (SCNT) — inserting the nucleus of an adult mammary cell into an egg cell with its own nucleus removed — to create Dolly, the first mammal cloned from an adult somatic cell. This proved that a fully differentiated adult cell retained the genetic instructions to build an entire organism, overturning a long-held assumption in developmental biology.
Why it matters: Dolly immediately triggered the modern human reproductive cloning debate — if a sheep could be cloned this way, could a human? Concerns about identity, individuality, psychological welfare of a cloned person, and "playing god" led most countries to explicitly ban human reproductive cloning, even while therapeutic cloning (creating cloned cells or tissues, not a full organism, for medical use) remains a separate and less restricted area of research.
Case 3: The CRISPR Gene Editing Controversy — Precision Editing, Imprecise Consequences
CRISPR-Cas9 gave scientists a fast, cheap, and precise way to edit DNA — but precision at the molecular level doesn't eliminate ethical complexity at the societal level. The core controversies are: the possibility of germline editing (heritable changes passed to future generations, most dramatically realized in the 2018 He Jiankui case, where embryos were edited without adequate ethical oversight); the risk of genetic enhancement (editing healthy embryos for non-medical traits, not just disease prevention); and unequal access (expensive gene therapies potentially available only to the wealthy).
Why it matters: CRISPR moved these debates from theoretical to urgent almost overnight, because the technology is accessible enough that oversight gaps in any single country can have global consequences — which is why international scientific bodies have called for a moratorium on heritable human genome editing until broader societal consensus and safety data exist.
Case 4: The GMO Food Debate — Safety, Choice, and Trust
Genetically modified crops raise a different kind of bioethics question — not about individual consent, but about collective risk and the public's right to know. The debate centers on three threads: safety (do GM foods pose health risks? — the scientific consensus, per major health and scientific bodies, is that approved GM foods on the market are as safe as their conventional counterparts), labelling (should consumers be told a product contains GM ingredients, even absent proven health risk, simply to support informed choice?), and acceptance (public skepticism toward GMOs often persists independent of the scientific safety evidence, driven by concerns over corporate control of agriculture and unfamiliarity with the technology).
Why it matters: This case shows that bioethics isn't only about harm — it's also about autonomy and trust. Even a technology broadly judged safe by regulators can remain ethically contested if the public feels it wasn't given a meaningful choice or clear information, which is exactly why GMO labelling law (not safety law) became the main battleground.
Case 5: Human Embryonic Stem Cell Research — Weighing Moral Status Against Medical Potential
Embryonic stem cells can develop into nearly any cell type in the body, offering extraordinary potential for regenerative medicine — but deriving them from an early-stage embryo (commonly surplus embryos from IVF procedures) destroys that embryo in the process. This forces a genuinely difficult question with no scientific answer: at what point does a developing embryo acquire moral status deserving of protection?
Why it matters: Because this is fundamentally a values question rather than a scientific one, policy responses have varied enormously by country and even changed over time within the same country (for example, shifting US federal funding restrictions between 2001 and 2009) — illustrating that some bioethics debates are unlikely to reach permanent consensus and instead require ongoing case-by-case regulatory review as alternatives (like induced pluripotent stem cells) also develop.
The Pattern Across All Five Cases
Read together, these cases reveal a consistent structure: a new capability emerges (immortal cell lines, cloning, precise gene editing, GM crops, pluripotent embryonic cells) faster than the ethical and legal framework needed to govern it. The response follows a similar arc each time — public controversy, scientific and philosophical debate, and eventually new guidelines, laws, or professional norms that try to catch up. Understanding this pattern is more useful for future exam questions and real-world reasoning than memorizing any single case, because it lets you predict how society is likely to respond to whatever the next biotech controversy turns out to be.
Key Terms
| Term | Definition |
|---|---|
| HeLa cells | An "immortal" human cell line derived without consent from Henrietta Lacks in 1951, widely used in research and central to modern informed consent debates. |
| Somatic cell nuclear transfer (SCNT) | The cloning technique used to create Dolly the sheep, transferring an adult cell's nucleus into an enucleated egg cell. |
| Therapeutic cloning | Cloning cells or tissues for medical use, without creating a full cloned organism — ethically and legally distinct from reproductive cloning. |
| Genetic enhancement | Editing genes to add or improve traits in an otherwise healthy individual, rather than to treat or prevent disease. |
| Induced pluripotent stem cell (iPSC) | An adult cell reprogrammed to behave like an embryonic stem cell, offering similar research potential without destroying an embryo. |
| Moral status | The philosophical question of what entities (e.g., embryos) deserve ethical consideration and protection, and at what stage. |
| Biobanking | The long-term collection and storage of biological samples (like HeLa cells) for research use, raising ongoing consent and ownership questions. |
Common Mistakes
Misconception 1: "The Henrietta Lacks case was illegal at the time, which is why it's controversial." Why it's wrong: This assumes today's ethical standards applied retroactively. Correct view: Taking tissue without consent was not illegal under the medical norms of 1951; the case is controversial precisely because it exposed how inadequate those norms were, which is why it helped drive the creation of the informed consent standards that would make such an action clearly wrong (and largely illegal in research contexts) today.
Misconception 2: "Dolly the sheep proves human cloning is scientifically ready and only ethics is holding it back." Why it's wrong: This overstates the technology's reliability. Correct view: SCNT cloning (as used for Dolly) has a high failure and abnormality rate even in animals, so significant unresolved technical/safety barriers exist alongside the ethical ones — it isn't purely an ethics-only barrier holding back human reproductive cloning.
Misconception 3: "Since GM foods are scientifically safe, the GMO labelling debate is unnecessary." Why it's wrong: This conflates safety with the separate issue of consumer autonomy. Correct view: Even when a product is judged safe by regulators, the ethical argument for labelling rests on the public's right to make informed choices about what they eat, independent of whether a health risk actually exists — autonomy and safety are different ethical grounds.
Comparison and Connections
| Case | Core Ethical Question | Main Outcome |
|---|---|---|
| HeLa cells | Consent and ownership of biological material | Informed consent norms, IRB review requirements |
| Dolly the sheep | Should organisms (and eventually humans) be cloned? | Global bans on human reproductive cloning |
| CRISPR / He Jiankui | Should heritable human genes be edited? | Calls for germline editing moratorium; criminal conviction |
| GMO food debate | Is safety enough, or is informed choice also required? | GMO labelling laws in many jurisdictions |
| Embryonic stem cells | At what point does an embryo deserve moral protection? | Shifting national policy; rise of iPSC alternatives |
Practice Questions
Recall
- Whose cells became the HeLa cell line, and in what year were they taken? Answer guidance: Henrietta Lacks's cervical cancer cells, taken in 1951 without her knowledge or consent.
- What cloning technique was used to create Dolly the sheep? Answer guidance: Somatic cell nuclear transfer (SCNT).
Understanding 3. Explain why the HeLa cell case remains ethically significant even though it wasn't illegal at the time. Answer guidance: It exposed a gap between accepted 1950s medical practice and basic respect for patient autonomy and consent; the case became a catalyst for the informed consent and IRB standards that now make such unconsented use of tissue clearly unethical (and largely illegal in research), showing how ethics can evolve ahead of and then reshape the law. 4. Why is therapeutic cloning treated differently from reproductive cloning in most legal frameworks? Answer guidance: Therapeutic cloning produces cells or tissues for medical use without creating a full organism, so it doesn't raise the same identity, welfare, and "designer human" concerns that reproductive cloning (creating a full cloned person) does — most bans target only reproductive cloning.
Application 5. A biobank wants to use leftover tissue from routine surgeries for future genetic research without recontacting each patient for every new study. Using the HeLa case as a reference point, what safeguard should be in place? Answer guidance: Broad or tiered informed consent obtained at the time of tissue collection, clearly explaining that the tissue may be used for a range of future research, reviewed by an IRB — this avoids the HeLa problem of using tissue with zero consent while remaining practical for biobanking. 6. A country is debating whether to allow therapeutic cloning for research but ban reproductive cloning. Using the Dolly case and its aftermath, justify why this split policy makes ethical sense. Answer guidance: Therapeutic cloning offers medical research benefits (e.g., generating patient-matched cells/tissues) without creating an individual whose welfare, identity, and consent to being cloned would need to be considered, whereas reproductive cloning directly creates a new person, raising unresolved welfare and identity concerns that Dolly's case first highlighted — the split allows scientific benefit while avoiding the sharper ethical risk.
Analysis 7. Compare the ethical concerns raised by the GMO food debate with those raised by embryonic stem cell research, and explain why one is primarily about safety/autonomy while the other is primarily about moral status. Answer guidance: The GMO debate centers on collective, societal-level concerns — is the food safe, and do consumers have a meaningful informed choice — where the scientific safety question is largely settled but the autonomy question remains live; embryonic stem cell research centers on an individual-level philosophical question — does an early embryo have moral status deserving protection — which has no scientific answer and instead depends on differing values and beliefs, explaining why policy varies so much by country. 8. Using the pattern "capability outpaces governance" identified across all five case studies, predict what kind of ethical/legal response a new, not-yet-invented biotech capability (e.g., functional gene drives released into wild populations) is likely to follow. Answer guidance: Based on the pattern, an initial period of limited or unclear regulation would likely be followed by a triggering controversy (e.g., an unintended ecological effect from a released gene drive), leading to public and scientific debate over risk and reversibility, and eventually to new guidelines or international agreements restricting or requiring extensive review before release — mirroring how Dolly triggered cloning bans and He Jiankui triggered germline editing moratorium calls.
FAQ
Q1: Did Henrietta Lacks or her family ever receive compensation for HeLa cells? For decades, no — the family did not know the cells existed or were being used commercially until years later, and while awareness and some settlements have since emerged, the case remains a landmark example of the gap between the commercial value generated by biological material and the rights of the person it came from.
Q2: Is human reproductive cloning legal anywhere? It is banned or heavily restricted in the vast majority of countries with relevant legislation, largely due to a global ethical consensus following Dolly the sheep about the welfare, identity, and safety risks of cloning humans.
Q3: What's the difference between somatic gene editing and the germline editing that caused the He Jiankui controversy? Somatic editing changes only the treated individual's cells and isn't inherited; He Jiankui edited embryos (germline editing), meaning the changes would be inherited by all of the resulting children's descendants — a far more ethically and legally fraught category.
Q4: If GM foods are considered safe by regulators, why do so many countries still require labelling? Because labelling addresses a different concern than safety — consumer autonomy and the right to make informed purchasing choices — which many policymakers consider a valid basis for labelling requirements independent of proven health risk.
Q5: Are induced pluripotent stem cells (iPSCs) a complete replacement for embryonic stem cells? Not entirely — iPSCs avoid the embryo-destruction ethical issue and have become extremely valuable for research and some therapies, but embryonic stem cells still have research applications (such as certain developmental biology studies) where iPSCs are not yet a perfect substitute, so both remain active areas of research.
Quick Revision
- HeLa cells (1951): taken from Henrietta Lacks without consent; sparked modern informed consent and IRB standards.
- Dolly the sheep (1996): first mammal cloned from an adult cell via SCNT; triggered global bans on human reproductive cloning.
- CRISPR / He Jiankui (2018): germline editing of human embryos without oversight; led to criminal conviction and calls for a global moratorium on heritable editing.
- GMO food debate: scientific safety consensus exists, but labelling debates persist over consumer autonomy and trust, not proven harm.
- Embryonic stem cell research: destroying an embryo to derive cells raises the unresolved "moral status" question; policy varies widely and shifts over time.
- Therapeutic cloning (cells/tissues) is ethically and legally distinct from reproductive cloning (a full organism).
- iPSCs offer a partial ethical workaround to embryonic stem cell debates but haven't fully replaced them scientifically.
- Common pattern across all cases: new capability arrives before governance, controversy forces catch-up, new norms become the next baseline.
- Genetic enhancement (non-medical trait editing) is ethically distinguished from genetic treatment (disease-related editing).
- Consent, moral status, autonomy, and justice are the recurring ethical lenses across all five case studies.
Related Topics
Prerequisites: Introduction to Ethical and Legal Issues, Ethics in Genetic Research
Related Topics: Intellectual Property Rights, Biosafety and Biosecurity, Regulatory and Compliance Issues
Next Topics: Apply these frameworks to emerging biotechnology topics such as synthetic biology and gene drives.